



IBA Launches AKURACY[®], an Integrated Solution for Cardiac PET Imaging at EACVI Meeting in Barcelona

The IBA AKURACY[®] is an innovative solution designed for the automated production of ¹³N-ammonia used for cardiac imaging.

Louvain-la-Neuve, Belgium, May 16, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, unveiled AKURACY[®], a unique integrated solution for PET myocardial perfusion imaging, at the European Association of Cardiovascular Imaging (EACVI) meeting in Barcelona, Spain. Cardiac PET (positron emission tomography) imaging is a fast-growing clinical tool endorsed by well recognized clinical guidelines and has demonstrated its high accuracy and precision. This powerful non-invasive imaging technique can assess myocardial blood flow (MBF) throughout the coronary circulation system, epicardial vessels and microvasculature, making it more effective and more efficient as a functional imaging modality.

AKURACY[®] is a fully integrated solution that combines PET production equipment, with a streamlined production process of ¹³N-ammonia, one of the most recognized radiotracers in cardiac imaging institutes worldwide. The system is a single button solution making it a convenient and efficient tool for on-demand production. It is designed to be operated by a trained technologist, with a ready-to-use ammonia dose produced approximately every ten minutes, resulting in a higher daily patient throughput and a better return-on-investment.

The benefits of PET imaging, including its accuracy, precision, high sensitivity and specificity, and patient-friendliness, were emphasized at the EACVI meeting, where cardiac imaging experts hailed the launch of AKURACY[®] as a major development in the field.

Bruno Scutnaire, President of IBA RadioPharma Solutions, added: *“IBA has installed over 350 cyclotrons worldwide and has extensive experience in supporting nuclear medicine departments. AKURACY[®] represents a new era in cardiac PET imaging, providing a complete and custom solution for healthcare facilities, with continuous support and maintenance to ensure the facility stays at the cutting edge of medical innovation.*

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Press release | May 15, 2023

1



IBA | Ion Beam Applications SA

Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Brabant-wallon

VAT : 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10

info@iba-group.com | iba-worldwide.com

Life,
Science.



More information can be found at: www.iba-worldwide.com

CONTACTS

Soumya Chandramouli

Chief Financial Officer

+32 10 475 890

Investorrelations@iba-group.com

Olivier Lechien

Corporate Communication Director

+32 10 475 890

communication@iba-group.com

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

IBA@consilium-comms.com